[go: up one dir, main page]

WO2003072731A3 - STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS - Google Patents

STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS Download PDF

Info

Publication number
WO2003072731A3
WO2003072731A3 PCT/US2003/005499 US0305499W WO03072731A3 WO 2003072731 A3 WO2003072731 A3 WO 2003072731A3 US 0305499 W US0305499 W US 0305499W WO 03072731 A3 WO03072731 A3 WO 03072731A3
Authority
WO
WIPO (PCT)
Prior art keywords
meningococcal
meningoccocal
immunogens
hbc chimer
hbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/005499
Other languages
French (fr)
Other versions
WO2003072731A2 (en
Inventor
Ashley J Birkett
Birgit Peck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apovia Inc
Original Assignee
Apovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apovia Inc filed Critical Apovia Inc
Priority to AU2003215395A priority Critical patent/AU2003215395A1/en
Publication of WO2003072731A2 publication Critical patent/WO2003072731A2/en
Anticipated expiration legal-status Critical
Publication of WO2003072731A3 publication Critical patent/WO2003072731A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid protein (HBc) is disclosed that contains an immunogen for inducing the production of antibodies to Meningococcal proteins. An immunogenic Meningococcal epitope is expressed between residues 76 and 85 of the HBc immunogenic loop sequence. The chimer preferably contains a Meningococcal-specific T cell epitope and includes a C-terminal cysteine residue for enhanced stability of self-assembled chimeric particles. Methods of making and using the chimers are also disclosed.
PCT/US2003/005499 2002-02-21 2003-02-21 STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS Ceased WO2003072731A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003215395A AU2003215395A1 (en) 2002-02-21 2003-02-21 STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35861802P 2002-02-21 2002-02-21
US60/358,618 2002-02-21

Publications (2)

Publication Number Publication Date
WO2003072731A2 WO2003072731A2 (en) 2003-09-04
WO2003072731A3 true WO2003072731A3 (en) 2005-02-10

Family

ID=27765969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005499 Ceased WO2003072731A2 (en) 2002-02-21 2003-02-21 STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS

Country Status (2)

Country Link
AU (1) AU2003215395A1 (en)
WO (1) WO2003072731A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476436T (en) 2006-08-11 2018-02-23 Life Sciences Res Partners Vzw IMMUNOGENIC PEPTIDES AND THEIR USE IN IMMUNE DISORDERS
ES2676630T3 (en) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Immunogenic control of tumors and tumor cells
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2356133B1 (en) 2008-10-10 2019-07-31 Zera Intein Protein Solutions, S.L. Recombinant protein bodies as immunogen-specific adjuvants
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
HUE055070T2 (en) 2010-11-25 2021-10-28 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
CN109069605B (en) 2016-04-19 2022-11-29 易姆赛斯股份公司 Novel immunogenic CD1d binding peptides
CN119841912B (en) * 2025-03-21 2025-06-27 北京华诺泰生物医药科技有限公司 Meningococcal outer membrane protein synthetic peptide and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399743A1 (en) * 1989-05-25 1990-11-28 Beecham Group Plc Phosphonomethylthio-alkoseypureine derivatives, intermediate products for their preparation and pharmaceutical compositions containing them
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
WO2001098333A2 (en) * 2000-06-22 2001-12-27 Celltech Pharmaceuticals Limited Modification of hepatitis b core antigen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399743A1 (en) * 1989-05-25 1990-11-28 Beecham Group Plc Phosphonomethylthio-alkoseypureine derivatives, intermediate products for their preparation and pharmaceutical compositions containing them
WO1999040934A1 (en) * 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
WO2001098333A2 (en) * 2000-06-22 2001-12-27 Celltech Pharmaceuticals Limited Modification of hepatitis b core antigen

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
MCGUINNESS B ET AL: "Deduced Amino Acid Sequences of Class 1 Protein (PorA) from Three Strains of Neisseria Meningitidis: Synthetic Peptides Define the Epitopes Responsible for Serosubtype Specificity", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 171, no. 6, June 1990 (1990-06-01), pages 1871 - 1882, XP002904209 *
PUMPENS ET AL: "Hepatitis B Virus Core Particles as Epitope Carriers", INTERVIROLOGY, vol. 38, no. 1-2, 1995, pages 63 - 74, XP002903139 *
SCHODEL ET AL: "The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity", JOURNAL OF VIROLOGY, vol. 66, no. 1, January 1992 (1992-01-01), pages 106 - 114, XP002090146 *
VAN DER LEY P ET AL: "Use of Transformation To Construct Antigenic Hybrids of the Class 1 Outer Membrane Protein in Neisseria meningitidis", INFECTION AND IMMUNITY, vol. 61, no. 10, October 1993 (1993-10-01), pages 4217 - 4224, XP002904208 *
WIERTZ ET AL: "Identification of T Cell Epitopes Occuring in a Meningococcal Class 1 Outer Membrane Protein Using Overlapping Peptides Assembeld wih Simultaneous Multiple Peptide Synthesis", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 176, July 1992 (1992-07-01), pages 79 - 88, XP002266481 *
WIERTZ ET AL: "T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins", INFECTION AND IMMUNITY, vol. 64, no. 1, January 1996 (1996-01-01), pages 298 - 304, XP002127427 *
ZLOTNICK ET AL: "Localization of the C terminus of the assembly domain of hepapatitis B virus capsid protein: Implications for morphogenesis and organization of encapsidated RNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 94, no. 18, September 1997 (1997-09-01), USA, pages 9556 - 6561, XP002982400 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Also Published As

Publication number Publication date
AU2003215395A8 (en) 2003-09-09
WO2003072731A2 (en) 2003-09-04
AU2003215395A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2002013765A3 (en) Malaria immunogen and vaccine
WO2005055957A3 (en) Influenza immunogen and vaccine
WO2002014478A3 (en) IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY
WO2003072731A3 (en) STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
WO2004075836A3 (en) STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
EP0992580A3 (en) Immunodominant human T-cell epitopes of Hepatitis C virus
WO2001098333A3 (en) Modification of hepatitis b core antigen
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
EP0271302A3 (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
WO2004053091A3 (en) STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
AU4270196A (en) Papilloma virus-like particles, fusion proteins and process for producing the same
AU2347997A (en) Synthesis and purification of hepatitis c virus-like particles
EA200300129A1 (en) CLEANING HEPATITIS B VIRUS ANTIGENS (HBV) FOR USE IN VACCINES
WO1993001210A3 (en) Hcv peptide-antigens and a method of testing for the hepatitis c virus (hcv)
CY1109257T1 (en) CHEMICAL PROTEINS L1 OF JUV 16 HUMAN PATIENTS CONTAINING L2 Peptide, Similar to Virus Particles Prepared by
WO2004048402A3 (en) A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
WO2003088995A3 (en) Mucin fusion polypeptide vaccines, compositions and methods of use thereof
WO1999050424A3 (en) Fusion protein comprising a sequence from a major coat protein of a papovavirus
WO2003102165A3 (en) IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
DE60333370D1 (en) FOR THE PRODUCTION OF PARTICLES CAPABLE OF HBV PRECORE PROTEIN
WO2001038358A3 (en) Hbv/hcv virus-like particle
WO2001070262A3 (en) A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
WO1997039029A3 (en) An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
HK126095A (en) Hepatitis a virus vaccines
WO2002088339A3 (en) Bursal disease virus-like particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP